Regentis Biomaterials Ltd.RGNT

$4.29-0.46 (-9.68%)
AMEXHealthcare24:00 UTC

Company snapshot

10-Year Price
-78%
2025 — today
52-Week Range
$1.28$9.04
Current $4.29· 39%

Regentis Biomaterials Ltd. is a regenerative medicine firm dedicated to crafting innovative solutions for tissue repair, ultimately aiming to enhance patients' health and overall quality of life. The company's primary product in development is GelrinC, a novel, cell-free, ready-to-use hydrogel designed to be solidified into an implant within the knee. This implant serves to address painful knee injuries and mend articular cartilage damage. Regentis Biomaterials leverages its proprietary Gelrin platform, which employs biodegradable hydrogel implants, to develop orthopedic therapies that facilitate the regeneration of compromised or diseased tissues. The company was established in 2004 and operates from its headquarters in Herzliya, Israel.

Valuation in context

No metrics available yet for RGNT.

Free · No credit card needed

Get alerted when RGNT is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.